Lantern Pharma Inc. Unveils AI Tool to Predict Cancer Drug Combination Efficacy

Lantern Pharma Inc. (NASDAQ: LTRN) has launched a groundbreaking artificial intelligence module aimed at predicting the efficacy of cancer treatment combinations involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). This innovative tool is part of the company's RADR(R) platform, which utilizes AI and machine learning to revolutionize oncology drug development. The module analyzes genomic, transcriptomic, and clinical data to forecast treatment synergy and patient response, significantly enhancing the precision of cancer therapies.

The development of this predictive algorithm was informed by a comprehensive review of 221 clinical trials, highlighting the potential of non-PARP DDRi combinations with DNA-damaging agents in treating specific cancer subtypes. Lantern Pharma's FDA-cleared Phase 1B/2 trial in triple-negative breast cancer has already benefited from this technology, showcasing its practical application in designing more effective treatment protocols.

With the global market for combination cancer therapies expected to exceed $50 billion by 2030, Lantern Pharma's AI module represents a timely and critical advancement in the field. The company is currently exploring licensing opportunities to make this technology available for broader use in oncology, potentially transforming how cancer treatments are developed and personalized for patients worldwide.

For more information on Lantern Pharma's innovative approach to cancer treatment, visit https://ibn.fm/LTRN.